<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Metabolic myopathies caused by disorders of lipid and purine metabolism
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Metabolic myopathies caused by disorders of lipid and purine metabolism
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Metabolic myopathies caused by disorders of lipid and purine metabolism
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Basil T Darras, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with metabolic myopathies have underlying deficiencies of energy production in muscle due to a wide variety of defects. These include defects in lipid, glycogen, glucose, adenine nucleotide, and mitochondrial metabolism [
         <a href="#rid1">
          1
         </a>
         ]. This topic will briefly describe fatty acid oxidation disorders (FAODs) (
         <a class="graphic graphic_table graphicRef114663" href="/z/d/graphic/114663.html" rel="external">
          table 1
         </a>
         ), which are inborn errors of metabolism resulting in failure of mitochondrial beta-oxidation or the carnitine-based transport of fatty acids into mitochondria. This topic will also summarize neutral lipid storage disease and lipin-1 deficiency, two other disorders of lipid metabolism. Myoadenylate deaminase deficiency, which affects purine metabolism, is also reviewed here.
        </p>
        <p>
         The clinical manifestations of the myopathies resulting from mitochondrial defects and from nonlysosomal and lysosomal glycogenoses are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">
          "Mitochondrial myopathies: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2941.html" rel="external">
          "Overview of inherited disorders of glucose and glycogen metabolism"
         </a>
         .)
        </p>
        <p>
         An overview of the clinical manifestations resulting from a metabolic myopathy and the approach to the patient suspected of having a metabolic myopathy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6193.html" rel="external">
          "Approach to the metabolic myopathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CARNITINE CYCLE DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The carnitine cycle shuttles long-chain fatty acids from the cytosol into the mitochondrial matrix where fatty acid oxidation occurs (
         <a class="graphic graphic_figure graphicRef59178" href="/z/d/graphic/59178.html" rel="external">
          figure 1
         </a>
         ). The presentations of carnitine cycle disorders vary with age; newborns and infants tend to present with more severe multisystemic disease triggered by infection or fasting, often with acute encephalopathy, liver failure, and cardiac involvement, while older children and adults tend to present with exercise-induced myalgias, weakness, and fatigue.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carnitine transporter deficiency
         </strong>
         is an autosomal recessive disease caused by pathogenic variants in the
         <em>
          SLC22A5
         </em>
         gene that encodes a high-affinity sodium-ion dependent organic cation transporter protein (OCTN2) expressed in heart muscle, kidney, lymphoblasts, and fibroblasts. Carnitine transporter deficiency is characterized by hypoketotic hypoglycemia, hyperammonemia, very low free and total plasma carnitine levels (usually less than 10 micromol/L), liver dysfunction, cardiomyopathy, and skeletal hypotonia. Presentation during the neonatal period is uncommon. Cardiomyopathy may be the presenting sign in children or young adults. A positive newborn screen for low free carnitine levels could be related to nutritional deficiency or carnitine transporter deficiency in the infant but also to low plasma carnitine levels in the mother from a vegetarian diet or undiagnosed maternal carnitine transporter deficiency [
         <a href="#rid2">
          2
         </a>
         ]. Carnitine transporter deficiency is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine transporter deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carnitine palmitoyltransferase 1A deficiency
         </strong>
         is an autosomal recessive disorder caused by pathogenic variants in the
         <em>
          CPT1A
         </em>
         gene, which encode a liver enzyme involved in fatty acid oxidation (
         <a class="graphic graphic_figure graphicRef99532" href="/z/d/graphic/99532.html" rel="external">
          figure 2
         </a>
         ). The most common phenotype is hepatic encephalopathy in childhood. Adult-onset myopathy is less common, and neonatal hypoglycemia is rare. Acute fatty liver of pregnancy can develop in female carriers if the fetus is homozygous for a pathogenic variant in
         <em>
          CPT1A
         </em>
         . Carnitine palmitoyltransferase 1A deficiency is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine palmitoyltransferase 1A deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carnitine acylcarnitine translocase deficiency
         </strong>
         is a rare autosomal recessive disorder caused by homozygous or compound heterozygous pathogenic variants in the
         <em>
          SLC25A20
         </em>
         gene. The onset of symptoms usually occurs in infancy or early childhood, and both heart and skeletal muscle involvement is observed. The initial manifestations usually occur in the neonatal period with acute encephalopathy, severe hypoketotic hypoglycemia, hyperammonemia, and ventricular arrhythmias. Patients may also develop progressive hypertrophic or dilated cardiomyopathy and skeletal muscle involvement. Carnitine acylcarnitine translocase deficiency is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine-acylcarnitine translocase deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carnitine palmitoyltransferase type 2 deficiency
         </strong>
         presents with hypotonia, cardiomyopathy, arrhythmias, seizures, and multiple congenital anomalies (dysmorphic facies, renal cysts, brain malformations) and may result in death during the first days to months of life [
         <a href="#rid3">
          3,4
         </a>
         ]. However, the majority of affected individuals have a later-onset form that presents in the second or third decade of life with exercise intolerance and attacks of rhabdomyolysis, which can lead to renal failure and death [
         <a href="#rid5">
          5,6
         </a>
         ]. Carnitine palmitoyltransferase type 2 deficiency is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine palmitoyltransferase type 2 deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          DEFECTS OF BETA-OXIDATION ENZYMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The intramitochondrial beta-oxidation defects involve the following enzymes [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Very long-chain acyl-coenzyme A dehydrogenase (VLCAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Very-long-chain acyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) and trifunctional protein (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Long-chain 3-hydroxyacyl-CoA dehydrogenase and trifunctional protein deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medium-chain acyl-coenzyme A dehydrogenase (MCAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Medium-chain acyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short-chain acyl-coenzyme A dehydrogenase (SCAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Short-chain acyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short-chain 3-hydroxyacyl-coenzyme A dehydrogenase (SCHAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple acyl-coenzyme A dehydrogenase (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Multiple acyl-CoA dehydrogenase deficiency'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electron transfer flavoprotein dehydrogenase (ETFDH)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electron transfer flavoprotein (encoded by ETFA and ETFB)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HMG-coenzyme A lyase [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Patients with defects in these enzymes may present with failure to thrive or hypotonia in infancy, or with exercise intolerance or weakness in older children and adults [
         <a href="#rid9">
          9
         </a>
         ]. These disorders are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H179423868">
         <span class="h1">
          NEUTRAL LIPID STORAGE DISEASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in the genes encoding two triglyceride lipases cause generalized lipid storage myopathy [
         <a href="#rid10">
          10,11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chanarin-Dorfman syndrome, also called neutral lipid storage disease with ichthyosis (NLSDI) is caused by pathogenic variants in the
         <em>
          ABHD5
         </em>
         gene (also called CGI-58) [
         <a href="#rid11">
          11
         </a>
         ]; patients present with congenital ichthyosiform erythroderma, hepatomegaly, lipid droplets in blood granulocytes (known as the Jordan anomaly), and increased levels of serum creatine kinase and liver enzymes. A subset of patients with NLSDI has muscle weakness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neutral lipid storage disease with myopathy (NLSDM) presents with juvenile-onset weakness and is caused by pathogenic variants in the
         <em>
          PNPLA2
         </em>
         gene [
         <a href="#rid12">
          12
         </a>
         ]. In NLSDM, the onset of weakness is usually late (after the first decade) and is typically characterized by marked shoulder girdle weakness, mild pelvic girdle and distal muscle weakness, and elevated serum creatine kinase levels [
         <a href="#rid13">
          13
         </a>
         ]. Multisystem involvement with cardiomyopathy, dyslipidemia, hepatomegaly, and/or diabetes is present in 20 percent or more of cases, though few patients have all these features combined [
         <a href="#rid14">
          14
         </a>
         ]. Case reports have described rare patients with variant phenotypes, including one with no weakness despite extensive lipid storage and markedly elevated creatine kinase levels [
         <a href="#rid15">
          15
         </a>
         ], two with a progressive myopathy with rimmed vacuoles [
         <a href="#rid16">
          16
         </a>
         ], and one with multisystem involvement including cognitive impairment [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Management is supportive, as there are no established treatments for these disorders [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H437406677">
         <span class="h1">
          LIPIN-1 DEFICIENCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipin-1 deficiency is an autosomal recessive disorder caused by pathogenic variants in
         <em>
          LPIN1
         </em>
         gene that usually present with recurrent rhabdomyolysis and myoglobinuria in young children, mostly in the setting of intercurrent infections with fever and, less frequently, with fasting or exercise [
         <a href="#rid18">
          18-20
         </a>
         ]. The episodes can be life-threatening. Lipin-1 deficiency-related episodes of myalgias and rhabdomyolysis may persist into adulthood [
         <a href="#rid18">
          18,21
         </a>
         ]. Adult onset is also reported [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Lipin-1 is a muscle-specific phosphatidic acid phosphatase that catalyzes the conversion of phosphatidic acid to diacylglycerol [
         <a href="#rid21">
          21
         </a>
         ]; thus, it is an important enzyme in the pathway of triglyceride and phospholipid biosynthesis. Lipin-1 also acts as a transcriptional protein that regulates cellular lipid metabolism, including genes involved in fatty acid oxidation and mitochondrial biosynthesis [
         <a href="#rid22">
          22
         </a>
         ]. Lipin-1 deficiency in muscle causes skeletal chronic myopathy in mice associated with abnormal mitochondria and exercise-induced elevation of plasma creatine kinase levels [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Creatine kinase levels can be very high (20,000 to 450,000 units/L), but carnitine levels, acylcarnitine profile, urine organic acids, and fatty acid oxidation studies are normal. Lipid content in muscle may be increased.
        </p>
        <p>
         The diagnosis of lipin-1 deficiency is confirmed by genetic testing. Management is supportive.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          MYOADENYLATE DEAMINASE DEFICIENCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myoadenylate deaminase (MADA) deficiency, a disorder of purine metabolism, is considered by some to be the most common metabolic myopathy, but this remains controversial. MADA deficiency is detected in approximately 2 percent of muscle biopsy specimens [
         <a href="#rid24">
          24
         </a>
         ]. This high prevalence of enzyme deficiency in muscle and the documentation of asymptomatic individuals have raised doubts regarding the clinical relevance of MADA deficiency. Nevertheless, the possibility of being pathogenic in certain patients because of the effect of other genetic or epigenetic factors cannot be excluded.
        </p>
        <p>
         Myoadenylate deaminase converts adenosine monophosphate to inosine monophosphate and ammonia. MADA deficiency results in decreased entry of adenine nucleotides into the purine nucleotide cycle during exercise [
         <a href="#rid25">
          25
         </a>
         ]. This enzyme has three tissue-specific subunits: E (erythrocyte), L (liver), and M (muscle). The gene that encodes for the M subunit (
         <em>
          AMPD1
         </em>
         ) maps to the short arm of chromosome 1 [
         <a href="#rid26">
          26
         </a>
         ]. MADA exists as an M homotetramer in human adult muscle. Pathogenic homozygous or heterozygous variants have been described; the heterozygous state is common and is found in approximately 10 percent of individuals of European or African descent [
         <a href="#rid27">
          27-29
         </a>
         ]. However, many individuals are completely asymptomatic, possibly because of alternative splicing patterns involving exon 2 of
         <em>
          AMPD1
         </em>
         [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Classic or primary myoadenylate deaminase deficiency is characterized by dynamic symptoms related to exertion and consists primarily of muscle aches and cramps which are sometimes very mild and poorly defined; it can also present with myoglobinuria [
         <a href="#rid31">
          31-33
         </a>
         ].
        </p>
        <p>
         Myoadenylate deaminase deficiency has also been noted in patients with other myopathies, such as Duchenne or Becker muscular dystrophy, phosphorylase deficiency, spinal muscular atrophy, or amyotrophic lateral sclerosis. In the latter group of patients, the myoadenylate deaminase deficiency appears to be secondary.
        </p>
        <p>
         Findings on laboratory examination include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resting serum creatine kinase level is usually normal or only slightly elevated
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electromyography is normal in most cases, or may show nonspecific myopathic changes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscle biopsy is histologically normal, but absence of MADA activity can be demonstrated by immunohistochemistry and direct muscle enzyme assay [
         <a href="#rid34">
          34
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The forearm ischemic exercise test shows a normal lactate curve, but no increase in the ammonia level or inosine monophosphate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecular genetic testing may reveal homozygosity or compound heterozygosity for
         <em>
          AMPD1
         </em>
         pathogenic variants [
         <a href="#rid27">
          27-29
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         There is no specific treatment for symptomatic MADA deficiency.
        </p>
        <p class="headingAnchor" id="H32366614">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with metabolic myopathies have underlying deficiencies of energy production in muscle due to a wide variety of defects, including defects in lipid metabolism (
         <a class="graphic graphic_table graphicRef114663" href="/z/d/graphic/114663.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carnitine cycle disorders include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carnitine transporter deficiency (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine transporter deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carnitine palmitoyltransferase 1A deficiency (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine palmitoyltransferase 1A deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carnitine acylcarnitine translocase deficiency (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine-acylcarnitine translocase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carnitine palmitoyltransferase 2 deficiency (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Carnitine palmitoyltransferase type 2 deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These deficiencies disrupt the carnitine cycle, which shuttles long-chain fatty acids from the cytosol into the mitochondrial matrix where fatty acid oxidation occurs (
         <a class="graphic graphic_figure graphicRef59178" href="/z/d/graphic/59178.html" rel="external">
          figure 1
         </a>
         ). The presentations of these conditions vary with age; newborns and infants tend to present with more severe multisystemic disease triggered by infection or fasting, often with acute encephalopathy, liver failure, and cardiac involvement, while older children and adults tend to present with exercise-induced myalgias, weakness, and fatigue. (See
         <a class="local">
          'Carnitine cycle disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intramitochondrial beta-oxidation defects involve the following enzymes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Very long-chain acyl-coenzyme A dehydrogenase (VLCAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Very-long-chain acyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) and trifunctional protein (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Long-chain 3-hydroxyacyl-CoA dehydrogenase and trifunctional protein deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medium-chain acyl-coenzyme A dehydrogenase (MCAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Medium-chain acyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Short-chain acyl-coenzyme A dehydrogenase (SCAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Short-chain acyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Short-chain 3-hydroxyacyl-coenzyme A dehydrogenase (SCHAD) (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple acyl-coenzyme A dehydrogenase (see
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Multiple acyl-CoA dehydrogenase deficiency'
         </a>
         ):
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Electron transfer flavoprotein dehydrogenase (ETFDH)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Electron transfer flavoprotein (encoded by ETFA and ETFB)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HMG-coenzyme A lyase
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with defects in these enzymes can present with metabolic decompensation, failure to thrive, or hypotonia in infancy, while adults can present with exercise intolerance or weakness. Additional manifestations may include cardiomyopathy or transient hepatic dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Beta-oxidation defects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115918.html" rel="external">
          "Specific fatty acid oxidation disorders", section on 'Medium- and short-chain fatty acid oxidation disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pathogenic variants in the genes encoding two triglyceride lipases cause generalized lipid storage myopathy, one associated with ichthyosis (Chanarin-Dorfman syndrome, also called neutral lipid storage disease with ichthyosis), the other presenting with juvenile-onset weakness (neutral lipid storage disease with myopathy). (See
         <a class="local">
          'Neutral lipid storage diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lipin-1 deficiency is an autosomal recessive disorder caused by pathogenic variants in
         <em>
          LPIN1
         </em>
         gene that usually presents with recurrent rhabdomyolysis and myoglobinuria in young children, mostly in the setting of intercurrent infections with fever and, less frequently, with fasting or exercise. (See
         <a class="local">
          'Lipin-1 deficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Classic or primary myoadenylate deaminase (MADA) deficiency is characterized by dynamic symptoms related to exertion and consists primarily of muscle aches and cramps which are sometimes very mild and poorly defined; it can also present with myoglobinuria. Asymptomatic or secondary myoadenylate deaminase deficiency is common, and thus the pathogenicity of MADA deficiency remains controversial. (See
         <a class="local">
          'Myoadenylate deaminase deficiency'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakoby M 4th, Jaju A, Marsh A, Wilber A. Maternal Primary Carnitine Deficiency and a Novel Solute Carrier Family 22 Member 5 (SLC22A5) Mutation. J Investig Med High Impact Case Rep 2021; 9:23247096211019543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albers S, Marsden D, Quackenbush E, et al. Detection of neonatal carnitine palmitoyltransferase II deficiency by expanded newborn screening with tandem mass spectrometry. Pediatrics 2001; 107:E103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelihan I, Rossignol E, Décarie JC, et al. Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD Rep 2022; 63:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mccormick BJ, Chirila RM. Carnitine palmitoyltransferase-II deficiency: case presentation and review of the literature. Rom J Intern Med 2021; 59:420.
          </a>
         </li>
         <li class="breakAll">
          Tein I. Lipid storage myopathies due to fatty acid oxidation defects. In: Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach, 2nd ed, Darras BT, Jones HR Jr, Ryan MM, De Vivo DC (Eds), Academic Press, San Diego 2015. p.761-795.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grünert SC, Schlatter SM, Schmitt RN, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: Clinical presentation and outcome in a series of 37 patients. Mol Genet Metab 2017; 121:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobon A. Metabolic myopathies. Continuum (Minneap Minn) 2013; 19:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMauro S, Garone C, Naini A. Metabolic myopathies. Curr Rheumatol Rep 2010; 12:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruno C, Bertini E, Di Rocco M, et al. Clinical and genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Commun 2008; 369:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer J, Lefèvre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 2007; 39:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilich P, Horvath R, Krause S, et al. The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. J Neurol 2011; 258:1987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massa R, Pozzessere S, Rastelli E, et al. Neutral lipid-storage disease with myopathy and extended phenotype with novel PNPLA2 mutation. Muscle Nerve 2016; 53:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akman HO, Davidzon G, Tanji K, et al. Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. Neuromuscul Disord 2010; 20:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohkuma A, Noguchi S, Sugie H, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve 2009; 39:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp LJ, Haller RG. Metabolic and mitochondrial myopathies. Neurol Clin 2014; 32:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michot C, Hubert L, Brivet M, et al. LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood. Hum Mutat 2010; 31:E1564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michot C, Hubert L, Romero NB, et al. Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis 2012; 35:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergounioux J, Brassier A, Rambaud C, et al. Fatal rhabdomyolysis in 2 children with LPIN1 mutations. J Pediatr 2012; 160:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Indika NLR, Vidanapathirana DM, Jasinge E, et al. Lipin-1 Deficiency-Associated Recurrent Rhabdomyolysis and Exercise-Induced Myalgia Persisting into Adulthood: A Case Report and Review of Literature. Case Rep Med 2020; 2020:7904190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris TE, Finck BN. Dual function lipin proteins and glycerolipid metabolism. Trends Endocrinol Metab 2011; 22:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweitzer GG, Collier SL, Chen Z, et al. Loss of lipin 1-mediated phosphatidic acid phosphohydrolase activity in muscle leads to skeletal myopathy in mice. FASEB J 2019; 33:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishbein WN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 1985; 33:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabina RL, Swain JL, Olanow CW, et al. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 1984; 73:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabina RL, Morisaki T, Clarke P, et al. Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem 1990; 265:9423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe M, Higuchi I, Morisaki H, et al. Myoadenylate deaminase deficiency with progressive muscle weakness and atrophy caused by new missense mutations in AMPD1 gene: case report in a Japanese patient. Neuromuscul Disord 2000; 10:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 1992; 89:6457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morisaki H, Higuchi I, Abe M, et al. First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient. Hum Mutat 2000; 16:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993; 91:2275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumeister FA, Gross M, Wagner DR, et al. Myoadenylate deaminase deficiency with severe rhabdomyolysis. Eur J Pediatr 1993; 152:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabina RL. Myoadenylate deaminase deficiency. A common inherited defect with heterogeneous clinical presentation. Neurol Clin 2000; 18:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashwal S, Peckham N. Myoadenylate deaminase deficiency in children. Pediatr Neurol 1985; 1:185.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6197 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738913" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Metabolic myopathies: a clinical approach; part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34032155" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Maternal Primary Carnitine Deficiency and a Novel Solute Carrier Family 22 Member 5 (SLC22A5) Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11389301" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Detection of neonatal carnitine palmitoyltransferase II deficiency by expanded newborn screening with tandem mass spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35028265" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16602102" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Disorders of carnitine transport and the carnitine cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34118800" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Carnitine palmitoyltransferase-II deficiency: case presentation and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34118800" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Carnitine palmitoyltransferase-II deficiency: case presentation and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28583327" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: Clinical presentation and outcome in a series of 37 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24305448" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Metabolic myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20676808" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Metabolic myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339307" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical and genetic characterization of Chanarin-Dorfman syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17187067" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21544567" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26600210" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neutral lipid-storage disease with myopathy and extended phenotype with novel PNPLA2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471263" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208393" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical and genetic analysis of lipid storage myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25037090" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Metabolic and mitochondrial myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20583302" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22481384" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22480698" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fatal rhabdomyolysis in 2 children with LPIN1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32549891" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lipin-1 Deficiency-Associated Recurrent Rhabdomyolysis and Exercise-Induced Myalgia Persisting into Adulthood: A Case Report and Review of Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21470873" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Dual function lipin proteins and glycerolipid metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30028636" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Loss of lipin 1-mediated phosphatidic acid phosphohydrolase activity in muscle leads to skeletal myopathy in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4004819" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Myoadenylate deaminase deficiency: inherited and acquired forms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6707201" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2345176" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Characterization of the human and rat myoadenylate deaminase genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10996775" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Myoadenylate deaminase deficiency with progressive muscle weakness and atrophy caused by new missense mutations in AMPD1 gene: case report in a Japanese patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1631143" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Molecular basis of AMP deaminase deficiency in skeletal muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11102975" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8486786" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2156480" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Metabolic causes of myoglobinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8335021" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Myoadenylate deaminase deficiency with severe rhabdomyolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10658174" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Myoadenylate deaminase deficiency. A common inherited defect with heterogeneous clinical presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3916903" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Myoadenylate deaminase deficiency in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
